ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2017) 52 P13 | DOI: 10.1530/endoabs.52.P13

Metachronous primary cancers in neuroendocrine tumour patients

Tracey Genus1,2, Catherine Bouvier1, Kwok Wong2, Rajaventhan Srirajaskanthan3, Brian Rous4,5, Denis Talbot6,7, Juan Valle8,9, Mohid Khan10, Neil Pearce11, Mona Elshafie12, Nicholas Reed13, Tu Vinh Luong14, Alia Munir15 & John Ramage3


1NET Patient Foundation, Leamington Spa, UK; 2National Cancer Registration and Analysis Service Public Health England, Birmingham, UK; 3Kings College Hospital, London, UK; 4Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 5National Cancer Registration Service, Cambridge, UK; 6University of Oxford, Oxford, UK; 7Oxford University Hospitals NHS Foundation Trust, Oxford, UK; 8University of Manchester, Manchester, UK; 9The Christie NHS Foundation Trust, Manchester, UK; 10University Hospital of Wales, Cardiff, UK; 11University Hospital Southampton NHS Foundation Trust, Southampton, UK; 12University Hospital Birmingham NHS Foundation Trust, Birmingham, UK; 13Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, UK; 14Royal Free London NHS Foundation Trust, London, UK; 15Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.


Introduction: Historically there has been an association with neuroendocrine tumours (NETs) and other cancers. However, this has not previously been well characterised. We aimed to determine the incidence of second malignancies in patients with NETs and investigate any association of the anatomical site of NETs with other malignancies.

Materials and methods: 12,844 patients were diagnosed with a NET between 2013 and 2015 and captured by the National Cancer Registration and Analysis Service (NCRAS). A count of tumours per person, and the most common sites for second malignancies was made. The relative risk of future site-specific NETs after non-neuroendocrine cancer was investigated.

Results: Of the 12,844 people in the analysis, 2,805 (21.8%) had at least one NET or non-NET, metachronous or synchronous cancer comprising: 2,311 patients with two cancers; 424 with three cancers; 61 with four cancers; seven with five cancers; and two with six cancers. The most common sites for metachronous cancer primaries were prostate (14.4%), breast (13.4%), non-melanoma skin cancer (12.0%), colon (11.4%), lung (5.5%), lymphoma (4.7%), kidney (3.8%), melanoma (3.4%), bladder (3.4%), rectum (3.3%), ovary (2.4%), endometrium (2.4%), leukaemia (2.0%), stomach (1.3%), thyroid gland (1.3%) and pancreas (1.1%). Eighty-one percent of patients had a second primary pre-NET diagnosis, 12% had a second primary post-NET diagnosis and 7% had a synchronous second primary. For males who had previously been diagnosed with prostate cancer the risk of site-specific NETs were as follows: bladder NET (RR 1.86 (CI: 1.33–2.62)); rectal NET (RR 1.47 (CI: 0.98–2.21)); pancreatic NET (RR 0.99 (CI: 0.73–1.36)); and small intestinal NET (RR 1.08 (CI: 0.84–1.36)).

Conclusion: Based on a large national cancer registry, most patients with NETs who presented with second cancers had pre-NET non-neuroendocrine primary cancers. This study identified prostate cancer as the most common site in male NET patients, and a possible association between prostate cancer and bladder neuroendocrine cancer needs further exploration.

Keywords: Neuroendocrine cancer; second primary; metachronous cancers; synchronous cancers